View Older Stories View More Recent Stories

Mar 9, 2022 04:01PM Intellia Therapeutics (NTLA) Granted FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
Mar 9, 2022 04:01PM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia 
Mar 1, 2022 07:30AM Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
Feb 28, 2022 04:02PM Intellia Therapeutics (NTLA) and Regeneron (REGN) Report Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulte
Feb 28, 2022 04:02PM Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustaine
Feb 28, 2022 04:01PM Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sus
Feb 24, 2022 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
Feb 23, 2022 08:06AM Intellia Therapeutics (NTLA) Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
Feb 23, 2022 08:00AM Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
Feb 17, 2022 07:30AM Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
Feb 15, 2022 07:39AM Intellia Therapeutics (NTLA), ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Feb 15, 2022 07:30AM Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Feb 3, 2022 07:30AM Intellia Therapeutics (NTLA) Announces Acquisition of Rewrite Therapeutics
Feb 3, 2022 07:30AM Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
Jan 6, 2022 07:46AM Intellia Therapeutics (NTLA) Highlights Strategic Priorities and Anticipated Development Milestones for 2022
Jan 6, 2022 07:30AM Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
Jan 5, 2022 04:01PM Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
Jan 5, 2022 07:31AM Intellia Therapeutics (NTLA), Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
Jan 5, 2022 07:30AM Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
Dec 20, 2021 07:30AM Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
Dec 13, 2021 07:30AM Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
Dec 9, 2021 07:00AM SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
Nov 22, 2021 07:32AM Intellia Therapeutics (NTLA) Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy
Nov 22, 2021 07:30AM Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
Nov 5, 2021 07:30AM Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
Nov 4, 2021 07:30AM Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Oct 28, 2021 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
Oct 21, 2021 07:30AM Intellia Therapeutics (NTLA) Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Oct 21, 2021 07:30AM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Oct 20, 2021 07:31AM Intellia Therapeutics (NTLA) Reports Promising Preclinical Data in its Broad Genome Editing Capabilities
Oct 20, 2021 07:30AM Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
Oct 13, 2021 07:02AM Intellia Therapeutics (NTLA) Collaborates with SparingVision to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Oct 13, 2021 07:01AM Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Oct 13, 2021 07:00AM Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Oct 12, 2021 07:30AM Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
Oct 6, 2021 07:30AM Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
Sep 27, 2021 07:30AM Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
Sep 16, 2021 07:31AM Intellia Therapeutics (NTLA) Announces U.S. FDA Acceptance of IND for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
Sep 16, 2021 07:30AM Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
Aug 31, 2021 07:30AM Intellia Therapeutics to Present at September Healthcare Investor Conferences
Aug 5, 2021 07:30AM Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Jul 29, 2021 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates
Jun 28, 2021 06:08AM Intellia Therapeutics (NTLA), Regeneron (REGN) Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy f
Jun 26, 2021 11:16AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 26, 2021 11:15AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 26, 2021 11:15AM Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR)
Jun 24, 2021 07:30AM Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
Jun 22, 2021 07:01AM Blackstone Life Sciences (BX), Cellex Cell Professionals, and Intellia Therapeutics (NTLA) Launch New CAR T-Cell Company
Jun 22, 2021 07:00AM Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
Jun 4, 2021 07:31AM Intellia Therapeutics (NTLA) to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
View More Recent Stories View Older Stories